美国FDA批准Camzyos(mavacamten)用于治疗纽约心脏病协会心功能分级为II-III级的有症状梗阻性肥厚型心肌病成人患者以改善功能和症状


camzios

联拓生物将继续在中国和亚洲其他地区开发和商业化Camzyos

Stay Connected With Us On Social Media Platforms For Instant Updates Click Here To Connect With Us TeaveterAnd Facebook

we are on now wire. Click here to join our channel (@TechiUpdate) And stay updated with the latest technology headlines.

for all the latest Health News Click Here

Follow us on Google News for the latest news and updates,

read original article here

Denial of responsibility! TechiLive.in is an automated aggregator around global media. All the material is available free of cost on the internet. We have arranged it on one platform only for educational purpose. In each material, a hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all content belongs to their authors. If you are the owner of the content and do not want us to publish your content on our website, please contact us E-mail – [email protected], Content will be removed within 24 hours.

Post FDA批准Camzios(MawacamtenII-III first appeared TechiLive.in,





Source link

Leave a Comment